The 1997 ANAO audit reveals that the industry was focused on comparator selection, the incorporation of wider qualitative economic benefits in the evaluation process, and the need to reduce submission churn to accelerate new listings. Sound familiar? …
The last audit shows why more process will never lead to faster access
July 26, 2023 Latest NewsBioPharmaComment
Latest Video
New Stories
-
The 'Dispatched' Week in Review Podcast - 19 June
June 19, 2026 - - Podcast -
Gilead rushes remdesivir to Uganda to support Ebola response
June 19, 2026 - - Latest News -
Infectious diseases across the lifespan are a hidden burden beyond the acute episode
June 19, 2026 - - Latest News -
Sanofi volunteers confront homelessness at Vinnies CEO Sleepout
June 19, 2026 - - Latest News -
Rhapsido approved in Australia as first oral targeted option for chronic spontaneous urticaria
June 18, 2026 - - Latest News -
Life sciences leaders brace for class action wave as dispute risks multiply
June 18, 2026 - - Latest News -
Is China's international benchmarking a bigger short-term risk to medicines access?
June 18, 2026 - - Latest News